50
Participants
Start Date
January 23, 2014
Primary Completion Date
May 4, 2021
Study Completion Date
August 29, 2024
Brentuximab vedotin
Brentuximab vedotin IV infusion
Semmelweis Egyetem, Budapest
Cliniques Universitaires Saint-Luc, Brussels
ZNA Stuivenberg, Antwerp
UZ Leuven, Leuven
Debreceni Egyetem Klinikai Kozpont, Debrecen
Pecsi Tudomanyegyetem, Pécs
Universitair Ziekenhuis Gent, Ghent
Clinical Hospital Centre Zagreb, Zagreb
Clinical Hospital Dubrava, Zagreb
Pamukkale Uni. Med. Fac., Denizli
Hospital Universitario Ramon y Cajal, Madrid
Istanbul Bilim University Medical Fac., Istanbul
Ege University Medical Faculty, Izmir
Dokuz Eylul University Faculty of Medicine, Izmir
Hospital Universitario de Salamanca, Salamanca
Erciyes University Medical Faculty, Kayseri
Hospital Universitario Marques de Valdecilla, Santander
Clinical Hospital Centre Rijeka, Rijeka
Policlinica de Diagnostic Rapid SA, Brasov
Spitalul Clinic Judetean de Urgenta Targu Mures, Târgu Mureş
Fakultni nemocnice Brno, Brno
Fakultni nemocnice Olomouc, Olomouc
Fakultni nemocnice Kralovske Vinohrady, Prague
Vseobecna fakultni nemocnice v Praze, Prague
Uniwersyteckie Centrum Kliniczne, Gdansk
Malopolskie Centrum Medyczne s.c., Krakow
SPZOZ MSW zWarminsko-MazurskimCen.Onko.wOlsztynie, Olsztyn
Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warsaw
Hospital de Braga, Braga
Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisbon
Centro Hospitalar do Porto, E.P.E. - Hospital de Santo Antonio, Porto
Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE, Porto
Spitalul Clinic Colentina, Bucharest
Spitalul Clinic Coltea, Bucharest
ICO lHospitalet Hospital Duran i Reynals, L'Hospitalet de Llobregat
Hospital Universitari Vall d'Hebron, Barcelona
Ankara University Medical Faculty, Ankara
Royal Cornwall Hospital, Truro
The Christie, Manchester
Birmingham Heartlands Hospital, Birmingham
Lead Sponsor
Takeda Development Center Americas, Inc.
INDUSTRY
Takeda
INDUSTRY